Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.

摘要: Abstract Objectives We conducted this single-institute; prospective, non-randomized parallel two-arm phase II study to evaluate the efficacy and safety of switch maintenance chemotherapy with S-1 after induction therapy a platinum-based regimen in patients advanced non-small cell lung cancer (NSCLC). Patients methods not showing disease progression received at dose 40mg/m 2 twice daily for 14 consecutive days, every three weeks, or without bevacizumab (Bev) 15mg/kg. In cases where contained Bev, Bev was used as continuation appropriate. The efficacy/toxicity S-1+Bev evaluated separately. primary end point treatment success rate months start treatment. Results Between July 2010 January 2014, 79 were enrolled, which 78 found be eligible inclusion study. 28.2% (90% confidence interval (CI), 7.1–17.1%) group 64.1% CI, 50.0–76.8%) group. endpoint met median PFS OS 2.6 11.0 group, 4.6 19.9 respectively. most common grade toxicity neutropenia (10% incidence group). There no febrile neutropenia. Conclusions Switch combination yielded modest mild acceptable toxicities.